1222. Risk Factors and Outcomes for Daptomycin Nonsusceptible Methicillin-Resistant Staphylococcus aureus Bloodstream Infections

BACKGROUND: Daptomycin (dap) has been approved and successfully used for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. However, reports of daptomycin nonsusceptible (DNS) MRSA strains have emerged over the recent years. This study describes the clinical characterist...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Open Forum Infect Dis
Asıl Yazarlar: Hadid, Hind, Rizvi, Hira, Misikir, Helina, Baratz, Nathalie, Bardossy, Ana Cecilia, Sundaram, Ayesha, Haddad, Lillian, Perri, Mary Beth, Zervos, Marcus, Herc, Erica
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2018
Konular:
Abstracts
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6253196/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.1055
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller